
Pfizer and the Department of Health – Abu Dhabi hosted a high-level workshop to advance real world data in healthcare research
The workshop brought together more than 60 researchers, data scientists, pharmacists, and healthcare professionals from across Abu Dhabi's leading hospitals and academic institutions to explore how real-world evidence (RWE) can be leveraged to advance research, improve health outcomes, and enable more personalized care.
The event served as a platform to foster knowledge exchange and scientific dialogue, and to support Abu Dhabi's ambition to become a global centre for health and life sciences. Through the MoU, Pfizer and DoH are working jointly to enhance real world data (RWD) capabilities, with a focus on driving local evidence generation and building research capacity that addresses both national and global healthcare priorities.
Dr. Nadine Tarcha, Medical Director at Pfizer Gulf, highlighted the company's role in shaping the future of healthcare research through meaningful partnerships. 'At Pfizer, we believe real world data is key to generating insights that complement clinical trials and accelerate patient-centred innovation. Through this collaboration with the Department of Health, we aim to empower local research, strengthen evidence generation, and improve access to better health outcomes.'
The workshop agenda included a range of expert-led discussions on the use of RWD from national databases, differences between RWE and traditional clinical trials, study design and bias, regulatory considerations, and governance models for data access. A panel discussion was also held featuring representatives from the Department of Health, the UAE Genome Program, M42, and global Pfizer RWE leaders to explore the potential of Abu Dhabi's Trusted Research Environment in advancing scientific discovery.
This initiative is part of a broader effort under the MoU to foster long-term public-private partnerships that enhance Abu Dhabi's global competitiveness in biomedical research, genomics, and precision medicine. It reinforces both entities' commitment to advancing data-driven solutions that improve health outcomes in the UAE and beyond.
About Pfizer Gulf
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 175 years, we have worked to make a difference for all who rely on us.
About the Department of Health – Abu Dhabi
The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Zawya
10 hours ago
- Zawya
Oman to produce medical diagnostic machines locally
A strategic Memorandum of Understanding (MoU) was signed by Dr Mohammad Mahmoodi, CEO of Carbon Technologies, and Dr Frank Vitzthum, Board Member and CTO of R-Biopharm, Germany, in the presence of Dr Rahma bint Ibrahim al Mahrouqiyah, Minister of Higher Education, Research and Innovation, on Tuesday. Under the MoU, advanced diagnostic manufacturing will be localised in Oman, supporting technology transfer and enhancing the country's health innovation ecosystem. The partnership will enable integration of state-of-the-art assay technologies into its local production lines, supporting both national and regional healthcare priorities. 'It is a milestone MoU in Oman's journey towards eliminating tuberculosis and other diseases from the country, and both communicable diseases and NCDs,' said Dr Rahma bint Ibrahim al Mahrouqiyah, Minister of Higher Education, Research and Innovation. 'I'm optimistic and this will pave the way for various scientific advancements in the country, especially when it is located near SQU and within the Innovation Park Muscat. We have begun, and we look forward to having an international consortium to eradicate both communicable and non-communicable diseases. We look forward to collaborating with regional, national and international partners so that we can cooperate with the leading players,' she added. Speaking to the Observer, Dr Mohammad Mahmoudi, Chief Executive Officer of Carbon Technologies, said that this collaboration is a testament to Oman's growing capacity in innovation-driven industries and its strategic openness to global partnerships. 'Together with R-Biopharm, we aim to elevate diagnostic standards, nurture Omani talent and contribute to national healthcare resilience,' Dr Mohammad added. Aligned with the objectives of Oman Vision 2040, the MoU supports national goals in biotechnology, scientific research and industrial innovation. Speaking on the sidelines of the signing ceremony, Eng Said bin Nasser al Salmi, Board Member of Carbon Technologies, said that the MoU would open up more opportunities to leverage Carbon Technologies as a leading Omani company and expand local R&D capabilities to serve both domestic and international markets in the healthcare industry and position Oman among the leading innovation hubs in such sectors. Dr Dirk Dressler, Head of Business Development at R-Biopharm AG, said, 'We are honoured to partner with Oman's Carbon Technologies. This collaboration reflects our confidence in Oman's capabilities and our shared commitment to delivering high-quality, accessible diagnostics across the region." 2025 © All right reserved for Oman Establishment for Press, Publication and Advertising (OEPPA) Provided by SyndiGate Media Inc. (


Al Etihad
2 days ago
- Al Etihad
Renowned orthopaedic experts bring advanced care to Abu Dhabi in August
11 Aug 2025 22:33 SAMIHAH ZAMAN (ABU DHABI)Patients looking for world-class orthopaedic care close to home can benefit from a duo of doctors headed to Abu Dhabi as part of the Department of Health – Abu Dhabi's (DoH) Visiting Physicians Munjed Al Muderis, a US-based consultant in orthopaedic surgery and Singapore-based Dr. Aymeric Lim, senior consultant of hand and reconstructive microsurgery, are seeing patients at two healthcare facilities in the capital, the DoH has announced. 'The DoH welcomes top-tier doctors from around the world to the Emirate during August, offering exceptions healthcare services through the Visiting Physicians Programme,' the authority announced. Dr. Munjed Al Muderis (L) and Dr. Aymeric Lim (R) Al Muderis practises at the St Mary Hosptial, Paley Institute at West Palm Beach, one of the largest centres in orthopaedics and limb lengthening in the United States. He specialises in limb lengthening, the treatment of diabetic feet, osseointegration for amputees, limb reconstruction, joint replacement, bone tumour treatment and paediatric orthopaedics. According to the DoH, he will see patients at the Burjeel Medical City between August 11 and part of the National University Hospital in Singapore, has 30 years of experience in micro hand surgeries, nerve surgery, tendon transfer, and the treatment of patients with severe crush or nerve injuries in the forearm. He will offer treatment services at the Sheikh Shakhbout Medical City between August 11 and DoH has urged patients and their families to directly contact the respective hospitals in order to book appointments. The authority's Visiting Physicians Programme – launched in 2021 with the aim of providing world-class care in Abu Dhabi – had enabled the treatment of over 3,200 patients in the emirate as of December 2024. Source: Aletihad - Abu Dhabi


Filipino Times
4 days ago
- Filipino Times
19 NCR DOH Hospitals Open Fast Lanes for Leptospirosis Cases
The Department of Health (DOH) announced that 19 of its hospitals in the National Capital Region have opened dedicated 'fast lanes' for leptospirosis patients to ensure quicker diagnosis and treatment. Leptospirosis is a bacterial infection spread through water contaminated by the urine of infected animals, often after exposure to floodwaters. Patients visiting these fast lanes will be assessed for possible admission and evaluated for the appropriate use of the antibiotic doxycycline. The list of hospitals includes major facilities in Manila, Caloocan, Las Piñas, Malabon, Mandaluyong, Marikina, Muntinlupa, Pasig, Quezon City, and Valenzuela. Among them are San Lazaro Hospital, East Avenue Medical Center, Lung Center of the Philippines, National Kidney and Transplant Institute, and Philippine Children's Medical Center. The DOH urged anyone who has been submerged in floodwaters or mud to seek medical consultation immediately. From June 8 to August 7, the agency recorded 2,396 leptospirosis cases nationwide.